| http://purl.uniprot.org/citations/35911442 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/35911442 | http://www.w3.org/2000/01/rdf-schema#comment | "Introduction: We aimed to explore the abnormal expression of dual-specificity protein phosphatase 1 (DUSP1) and its latent molecular mechanisms in ovarian carcinoma (OVCA). Materials and Methods: Two clinical cohorts collected from two different hospitals were used to evaluate the expression of DUSP1 protein in OVCA tissues. RNA-sequencing and microarray datasets were utilised to verify DUSP1 expression at mRNA levels in both OVCA tissues and in the peripheral blood of OVCA patients. Furthermore, an integrated calculation was performed to pool the standard mean difference (SMD) from each cohort in order to comprehensively assess the expression of DUSP1 in OVCA. Furthermore, we examined the relationship among DUSP1, tumour microenvironment (TME), and chemotherapy resistance in OVCA. Moreover, we used pathway enrichment analysis to explore the underlying mechanisms of DUSP1 in OVCA. Results: A pooled SMD of -1.19 (95% CI [-2.00, -0.38], p = 0.004) with 1,240 samples revealed that DUSP1 was downregulated in OVCA at both mRNA and protein levels. The area under the receiver operating characteristic curve of 0.9235 indicated the downregulated DUSP1 in peripheral blood may have a non-invasive diagnostic value in OVCA. Through six algorithms, we identified that DUSP1 may related to tumour-infiltrating T cells and cancer associated fibroblasts (CAFs) in OVCA. Pathway enrichment demonstrated that DUSP1 might participate in the mitogen-activated protein kinase (MAPK) signalling pathway. Furthermore, DUSP1 may have relations with chemotherapy resistance, and a favourable combining affinity was observed in the paclitaxel-DUSP1 docking model. Conclusion: DUSP1 was downregulated in OVCA, and this decreasing trend may affect the infiltration of CAFs. Finally, DUSP1 may have a targeting relation with paclitaxel and participate in MAPK signaling pathways."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.org/dc/terms/identifier | "doi:10.3389/pore.2022.1610404"xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Chen G."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Chen J.H."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Li J."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Shi L."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Huang S.N."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Huang Z.G."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Zhong L.Y."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Liang Z.Q."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Luo J.Y."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Zeng J.J."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "He R.Q."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Zeng J.H."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/author | "Wei K.L."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/date | "2022"xsd:gYear |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/name | "Pathol Oncol Res"xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/pages | "1610404"xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/title | "Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods."xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://purl.uniprot.org/core/volume | "28"xsd:string |
| http://purl.uniprot.org/citations/35911442 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/35911442 |
| http://purl.uniprot.org/citations/35911442 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/35911442 |
| http://purl.uniprot.org/uniprot/#_B4DU40-mappedCitation-35911442 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35911442 |
| http://purl.uniprot.org/uniprot/#_B4DQ64-mappedCitation-35911442 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35911442 |